School of Medical Sciences Seminar Series
Speaker: Marc Wilkins, School of Biotechnology and Biomolecular Science, UNSW Sydney
Bio: In 1994, Marc Wilkins developed the concept of the proteome and coined the term. In 1997 he co-wrote and lead-edited the first book on proteomics, which in 2007 was published in second edition. Wilkins has now published >230 peer-reviewed research papers, reviews and book chapters in the fields of proteomics, genomics / transcriptomics and in systems biology. In proteomics, he has a focus on the functional analysis and regulation of protein methylation and on the dynamics of protein-protein interaction networks.
Wilkins serves on the advisory and management boards of organisations including the Australian Proteome Analysis Facility, the Futures Institute in Cellular Genomics and Bioplatforms Australia. He has acted as an advisor to the New South Wales State Government and the Government of New Zealand. He has been elected to the council of HUPO (the Human Proteome Organisation) four times, is a current council member, and was co-organiser and program chair of the international congress HUPO2010 (Sydney) and a co-organiser of HUPO2019 (Adelaide). He is an elected member of the management committee of the Australian Proteomics Society and a co-organiser of its annual conference. Wilkins was a senior editor of the Wiley journal PROTEOMICS for a 10 year period.
In industry, Wilkins has co-founded two biotechnology companies. Proteome Systems Ltd, established in 1999, developed proteomics technology and a platform for rapid point-of-care diagnostic testing. Regeneus Pty Ltd, established in 2007, has developed an adult stem cell product which has recently been licensed to a major partner in Japan. Wilkins has been the director of the Ramaciotti Centre for Genomics since 2011, a centre which is now the largest at any Australian university.
Abstract: Protein methylation is one of the most widespread modifications in the eukaryotic cell, although one which is relatively poorly understood. Functionally its role is best - characterised in histone proteins, ribosomal proteins and proteins involved in RNA splicing and transport, yet it is found on proteins involved in many other processes. The dysregulation of methylation is strongly associated with cancer and with metabolic, neurodegenerative and muscular disorders.
This talk will describe how we have used proteomics to build and characterise a near-complete eukaryotic network of protein methylation. It will describe the process of methylation discovery in the entire proteome, how we have discovered new eukaryotic protein methyltransferases and then
determined their target proteins and recognition motifs. The talk will also discuss investigations into the
regulation of methylation-associated processes, which we have studied through examining the
phosphorylation of methyltransferases and, also crosstalk between methylation and phosphorylation.
Finally, the talk will explore how large-scale crosslinking mass spectrometry is providing new means to
study protein methylation and, also the relationship between genotype and phenotype.